In one paragraphArticle in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Kodai AbeDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.
Kelly ChongDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.ORCID 0009-0001-6219-4088 Minoru KitagoDepartment of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.ORCID 0000-0002-4909-1199 Motonori EdanamiDepartment of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
Yosuke UematsuDepartment of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
Yohei MasugiDepartment of Pathology, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
Akihisa UenoDepartment of Pathology, Tokai University School of Medicine, Isehara 259-1193, Kanagawa, Japan.ORCID 0000-0001-9428-4128 Matias A BustosDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.ORCID 0000-0001-9625-1127 Anton J BilchikDepartment of Gastrointestinal and Hepatobiliary Surgery, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.ORCID 0000-0002-7251-2828 Yosef ShilohDavid and Inez Myers Laboratory for Cancer Genetics, Department of Human Genetics and Computational Medicine, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel.ORCID 0000-0002-1538-6060 Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
Dave S B HoonDepartment of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.
Funding
Cori foundationDr. Mariam and Sheldon Adelson Medical Research FoundationNakayama Foundation for Human Science
6 · The paper itselfAbstract
backgroundIntrahepatic cholangiocarcinoma (iCCA) is an aggressive biliary tract malignancy with limited treatment options and poor prognosis. Platinum-based drugs are one of the major therapies; however, resistance remains a major therapeutic challenge. Ubiquilin-4 (UBQLN4), a ubiquitin-binding protein implicated in cancer progression and DNA damage responses, is located at chromosome 1q22, a region recurrently amplified in several cancers. We investigated the clinical and functional relevance of UBQLN4 in iCCA.
methodsPublic datasets (TCGA-CHOL and GSE107943) were analyzed to identify genomic alterations and
resultsChromosome 1q22, containing
conclusionsElevated
Indexed as
Adaptor Proteins, Signal TransducingBile Duct NeoplasmsBiomarkers, TumorCell Cycle ProteinsCholangiocarcinomaCisplatinDrug Resistance, NeoplasmCarrier ProteinsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleNuclear ProteinsPrognosisAdaptor Proteins, Signal TransducingBiomarkers, TumorCarrier ProteinsCell Cycle ProteinsCisplatinNuclear ProteinsUBQLN4 protein, humancisplatinCNVintrahepatic cholangiocarcinomaneoadjuvant chemotherapyUBQLN4
Identifiers
PMID42782797
PMCPMC13605264
What OpenQuestion holds
Textmetadata
Read underepoch 390